Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - heparinoidum ex organis animal - hlaup - 3 mg/g

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - finasteridum inn - filmuhúðuð tafla - 5 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - sevelamerum karbónat - filmuhúðuð tafla - 800 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 1 g

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - atovaquonum inn; proguanilum hýdróklóríð - filmuhúðuð tafla - 250/100mg mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - cetirizinum díhýdróklóríð - filmuhúðuð tafla - 10 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - finasteridum inn - filmuhúðuð tafla - 1 mg

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

sun pharmaceutical industries europe b.v. - meropenemum tríhýdrat - stungulyfs-/innrennslisstofn, lausn - 500 mg

Europeiska unionen - isländska - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - sýkingar af völdum sýklalyfja - bóluefni - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.

Island - isländska - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - sodium cromoglicate - augndropar, lausn - 20 mg/ml